Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
<spent: Just wait until CYGX files their IND for Simplivir...that should happen in 2014 or so.>
Lol, bigworld. I know, by that time the share count of CYGX will be as bigger than MSFT and GE's, because at least those companies are buying back stock instead of just issuing it.
<How is it that people used a CYGX product years ago to cure/control herpes and shingles but we are still no where near even filing an application to begin clinical trials?>
I really don't know, nearlynapping. That is the "great mystery." Science today is amazing, but when you hear something like that it can sometimes be too good to be true. Only tim will tell.
A CURE FOR HERPES!!?!!
Is CytoGenix and other companies too late to the ballgame? Has a cure for herpes really been found? It sounds a bit sketchy and too good to be true, however this product has gotten the attention of the FDA, and they have granted a IND to this company.
http://news.yahoo.com/s/prweb/20060807/bs_prweb/prweb420811_1
Any thoughts?
CYGX TO REVERSE SPLIT
At the rate that CYGX's share count is being dilluted, I think it is inevitable that management will eventually reverse split the stock.
Reverse splits are not usually a good thing, at least not temporarily for shareholders. As most of you I'm sure know, a reverse split is done primarily to boost a stock's share price, if management believes that the stock is a dud with its current shares outstanding and valuation. Reverse stock splits are usually signs of a company indirectly putting itself up for sale. An example of this was AT&T, which after reverse spliting a couple of years ago was bought out by rival SBC, which kept AT&T's name. The new AT&T stock is still a dud like its predecessors.
However, reverse stock splits are not always bad for investors either. 7-Eleven, reverse split its shares back in 2000. After the company's stock price fell precipitously for the first 2 years, the shares rebounded nearly 10 fold over the last three and half years, until the chain was finally acquired by its parent company last year.
PANC, the biotech that allegedly has HIV "running scared" reversed split its shares 1 for 10 just last year. The company has since gone on to post impressive data about its drug candidates, improved its balance sheet, and rewarded patient investors with a commendable rise in its stock price. However, PANC is now rumored to be a buyout target by bigger drug firms. One specifically being GILD.
CYGX is unfortunately resorting to means of financing that are dilluting its share count immensely. Despite the stock faring rather well over the last 3 years, I believe that the dillution will soon start to take its toll on the shares. Unless CYGX garners legitimate sources of capital backing, we will see the company reverse split its shares. I think the reverse split will come when CYGX's current share count increases 5 fold or more. Judging by the reverse splits carried out by other companies, CYGX's reverse split could or could not be a good thing. It will be interesting to see.
KILAUEA YOU SPELLED TRANSPARENT WRONG!
LOL! Hey, my last post is far from bashing (#35006). I am merely citing the truth about this company. Which is, as I said, they appear to be spreading themselves too thin. CYGX has all these projects going on but hardly any revenue, and certainly no drug candidates to show from it. Hopefully, someday this will change, but for now the stock price is being dictated by press releases and no real solid data. Except maybe for the GE deal but CYGX has not disclosed that they are partnering with them on any specific drugs yet.
Judging by your past posts(such as #35015), kilauea, you appear to be a person who is using these message boards to vent, because you're not making a quick buck overnite. You don't offer any legitimate or logical arguments instead you just spew passion and hateful rhetoric to posters who are trying to offer realistic perspectives about these stocks, by calling them "bashers." Your style is immature and perhaps you should consider the Yahoo boards (if you haven't already), because unfortunately they are filled with people like you. These boards are for intelligent and mature conversations.
Please get a grip and wise up, Sir.
CYGX SPREAD TOO THIN?
Some of you on this board seem very knowlegeable of what is going on with this company so please help me out.
First off, for those of you who do not know, I have been a loyal shareholder of this company for many years now, and I still believe that CYGX has the potential to blossom into a legitimate biotech someday and trade on a major market.
However, I remember way back in the day, when CYGX seemed to be primarily focused and determined to bring their Herpes treatment drug to market asap. There was even talk of the potential of phase 2 studies being skipped because CYGX's technology was so safe and convincing.
While animal studies of the Herpes treatment appeared successful, an array of other projects began to pop up from CYGX. After herpes came HPV, then drug resistant bacteria, then cancer, then HIV, then the selling of their cheap but efficient dna, then agricultural bacterium, now the bird flu. Is there something I missed?
According to their recent report, CYGX is not going to file an IND for their once highly touted "herpes panacea" until late 2007! I remember when they were saying that they were going to file this IND in 2005.
Not to drag on, but correct me if I'm wrong, hasn't CYGX lost it's focus? Why doesn't it just concentrate on getting some legitimate drug candidates into human studies and partnering with a big time pharma or biotech company before running around making all these deals that are amounting to hardly any revenue. While the shares outstanding continue to rise because all CYGX can do is sell debt and give out options.
The stock has had a nice run, but if the company continues on this route I'm sure something is bound to give sooner or later and it won't be pretty for shareholders.
Where am I going wrong here? Thanks.
CYGX's CASH SURGES!!!!
Apparently helped by the GE deal, CYGX's cash on hand has surged from $685.45K to an all time high of $1.31M. This is good news, however, I am assuming that options were also cashed out causing outstanding shares to rise and dillute the stock count.
It is good to see the cash reserves rising, however, management needs to utilize this money and get those drug candidates lingering in pre-clincial status into Phase 1. They also need to update us on the progress of the $2M facility they said they were building nearly a year ago. These things do take time, so I guess we really need to be patient.
CYGX stock has had a great 6 months! No complaints here.
Anyone know about CYGX's lead product candidates?
CYGX's pipeline is still a big question to me. All the news wires that we've received lately have been great. Especially the GE Healthcare pact, which finally gives some concrete substance to CYGX as a legitimate biotech, because GE is not going to partner with just anyone. However, what about the lead product, the herpes cream, or the sepsis treatment? We have not heard anything about these products and for the past few years that is basically all CYGX has been trying to be renound for is their herpes treatment. The pipeline on CYGX's home website says 2005 for the herpes product, but obviously we are no longer in that year so what's the deal? Anyone know?
Bigworld: I agree.
Something is not right here and both your reasons are shaping up to be unfortunately true. I really do not understand what CYGX is doing now? They've boasted that their technology has worked so well in preclinical trials with animals, but with nearly 2 months left before they are supposed to apply for the IND we hear nothing from them. I am hoping that they want to surprise all of us loyal investors, but the situation with this conference is really clouding my optimisim. Meanwhile Malcom and company keep getting more and more stock options that are doing nothing but dilluting the share count and making them richer.
This is very good detective work that you have done. Please keep us informed of what you find out. I am going to be calling CYGX on Monday bright and early to see if I can talk to anyone, I am also going to email them this weekend. The next step after that will be literally beating on their door for answers.
spent
Give'em a call!
CytoGenix, Inc.
3100 Wilcrest Drive, Suite 140
Houston, Texas 77042
Phone: (713) 789-0070
Fax: (713) 789-0702
I have noticed that there is a tremendous amount of frustration on this message board as of late and I certainly understand why.
CYGX has been awfully quiet for too long. According to what they have said in old news releases and what the pipeline indicates on their website, they should be filing an IND for their Herpes "panacea" product this year. They have about 2 and half months left to do so on time and we have not heard a peep from them, which usually means unfavorable news for a company keeping so quiet. By not answering simple emails is also extremely suspect as well.
I commend many of you for doing your homework and digging into what is going on with this company since they are not talking. I have made cameos on this message board for the last 2 years and I am always impressed by the intelligent and pertinent postings I read
I hope that I am wrong, but there definitely seems to be something fishy going on here and it is really too bad, because many of the markets that CYGX's "potential products" are targeting are up for grabs. Especially herpes. I can only name a few companies that are even attempting to combat herpes and most of them are "Cytogenix-like" companies that are extremely small, not even publicly traded, and have products in very early development phases. The only legitimate drug company with a potential product that might be out soon is GSK with their Herpes Vaccine, but that is allegedly only working in women and is for females who are not yet sexually active or infected, so basically for young children.
I am glad that the option situation is finally being brought to light also. I cringed at how many shares CYGX has outstanding and how many options they are giving away. I think they will eventually issue a reverse split to lessen the count, but that will most likely be after all the officers sell.
To sum this up, if the company is not returning emails we should just call them up or flood their mailboxes and fax machines with messages. I was even thinking of showing up at their doorstep and demanding to speak with someone legitimate. The company is certainly small enough and I remember Skolnick saying in an email that they invite any shareholder to stop by if they are in the neigborhood. I don't know if any of you remember that email, but I bet Skolnick and his staff do and they might be regreting that they wrote it now. LOL.
Keep the news coming.
spent
CYGX TO REVERSE SPLIT!!!!!!!!!!!!!!!
I believe that this company will be carrying out a reverse split fairly soon. A lot of small biotech companies do this because they hand out options like crazy to keep the talent and this leads to major dillution of the stock. Also, a revese split would cause CYGX's share price to rise so it can potentially abandon its OTC status and reap the investments from players of major firms.
CYGX looks like it has just under 110 million shares outstanding. That is a great deal of shares on the market for a company that does not even have a product in phase 1 trials yet and is claiming to have only a sliver of cash on its balance sheet. However, it is good to see that CYGX has not taken on any substantial debt yet.
CYGX DILLUTED?
Cytogenix appears to have great potential, but does this company really have 95.7 million shares outstanding?
If so, that is an awful lot of shares for a company that has no earnings and no products that have reached Phase I of development.
There are countless other biotechs out there that have plenty of products in late stage development as well as products on the market and some of these companies don't even have a share outstanding count that is a third of CYGX's.
Will this apparent dillution hinder CYGX's share price?
I think it is safe to assume that it won't help it.
A legitimate stimulus!
The year end message from Dr. Skolnick was certainly a tremendous and welcomed stimulus for Cytogenix stock.
Does anyone know, or have any suspicions about, who the drug companies are that CYGX is in talks with for a partnership for Simplivir(TM) and the anti-bacterial agent?
I guess we have to assume that it is an asset-backed behemouth, with perhaps a dry pipeline, but a ton of cash, such as a PFE, BMY, MRK or SGP.
Or do you think it is a much smaller player who is just looking to expand, like AGEN or VRTX?
I would not be surprised if it was GSK, because they are big into the herpes and sepsis market and have several drugs in their pipeline to combat these diseases.
Thanks neo43.
I appreciate your support.
Bigworld.
<<<Just a side note. I hope this "hub" continues to be a forum for information, the respectful exchange of views, opinions and ideas, that the regular posters have been engaged in for some time. I had read this forum for many months before and during my 4 month accumulation and I found some good info and ideas. I hope it never degenerates into the filth, name calling and stupidity of the Yahoo message boards.
Happy holidays to all. May 2005 be a healthy and very, very prosperous year for all.>>>
Well written. I agree one hundred percent!
The CYGX board has been great along the lines of offering information in a professional manner and engaging in civil conversation.
I think the positivism on this board has exuded from the fact that everyone who contributes wants CYGX to succeed. Unlike some of the Yahoo boards that unfortunately attract some posters who seemingly have no interest in the particular company and just want to make trouble with the people who do.
Since the posters on this board share the same sentiment I think it is important that we all do not succumb to a "group think" mentality towards CYGX and deem this company and stock invincible and start buying like maniacs everytime they come out with a new disclosure to the public. This mindset is hazardous because it could blind us to any peril that might befall this stock and cause us all to loose our shirts.
CYGX has seemingly always had the potential of being a very, very exciting company and now that they are just starting to produce it is easy to get passionate about this stock, because we are all looking for the news that will make this stock break out big time.
Like the rest of you, I certainly want CYGX to eventually hit $100!
Therefore, we need people to dissent and provide an alternative way of looking at CYGX especially when good news is disclosed by the company to the public. I served as the dissenter the other day when CYGX more than doubled when they announced the DNA lab situation and I was labeled a shorter by some, however my predictions came true. I am not dwelling on this, I do not have a problem with anyone who challenged me, and I think it is great that I was challenged because that shows that my point of view was at least acknowledged, if not followed. However, I definitely want to move on, but my point is is that I hope more of you can serve as dissenters when things really get going with this stock so the rest of us can keep a cool head. Being a dissenter is not necessarily being negative, but definitely being logical.
Good news told to the public by a company does not always translate into a profit for investors!
Thanks to all of you, I appreciate it.
peace_2_all
Thank you.
I appreciate your positive backing.
Told you!
As CYGX's stock price continues to fall I knew this was going to happen, but I was shunned the other day on this board by some who disagreed with me.
No problem, opinions certainly vary, however, the fact is that fools rushed in and overbought.
Don't get me wrong, the news was good, but I did not think it warranted the stock to double in 2 days.
I want to see the human trials start and for the FDA to allow CYGX to combine Phases I and II as rumored, then maybe this stock can reach 50 cents.
Until then expect CYGX to fall or find a bottom just below its current levels or perhaps even back in the 20 cent range.
For all long termers like myself, I suggest you continue to build a position as CYGX falls. I do believe the company has a bright future.
Sorry Paulness,
but I actually did not sell a month ago or ever. As I said, I am a long-term share holder of CYGX because based on what I have read I believe that they will eventually succeed.
I've bought as high as 70 cents and have been building a steady position all along, especailly since the summer and all fall when CYGX has been languishing in the 31 to 26 cent range.
Although I appear to be taking the role of a buzz kill, bear, shorter, I really am quite the opposite. However, I don't want to see shades of 1999 technology themes with the stock when people jumped the gun and bought on any news that seemed positive.
Be cautious of CYGX!
As a loyal shareholder of CYGX, I am certainly happy about the news disclosed by the company yesterday and the recent surge in the stock price.
However, CYGX has an awfully long way to go before the company actaully starts producing anything. One can argue that a revolutionary break through DNA lab is a tremendous start, but it is not allowing the company to presently reap any monetary revenue. We don't even know if this new plant works because CYGX does not even have one drug in human clinical trials.
News that would weigh more heavily with me would be CYGX disclosing that the FDA is allowing them to proceed with human trials of their first drug and because of their DNA technology they are allowed to combine Phases I and II, which would reduce time and R&D expenses significantly in the drug's production.
I believe something like this will eventually happen next year, but we will see.
High aspirations and promises will get you only so far and then only earnings is what matters.
From what I have read and researched about CYGX, I believe that the company is truly unique and has a very bright future if this DNA technology that they have works against the diseases that they are targeting. But I would not advise investors to go gun ho about this stock just yet based on this DNA plant news alone.
I personally have seen too many OTC stocks come and go.
CYGX certainly seems to have the potential to be an exception, but only time will tell.
Watch yourselves.
HERPES RATES COULD EXPLODE BY 2025!
http://www.ajc.com/health/content/shared-auto/healthnews/herp/509619.html
CytoGenix has a tremendous opportunity if their technology works.
Young Man Given The Cure For Herpes And Cold Sores?
http://news.yahoo.com/news?tmpl=story&u=/040616/234/776g8.html
I went to this website (below) which sells this Viraway and Immune Builder products and they call themselves The Institute For Better Health (IFBH).
http://www.viraway.com/
Has anyone ever heard of the IFBH or these Viraway and Immune Builder Products?
They're over the counter so I am a bit suspect but does something like this put CYGX against the wall? Let me know what you all think.
Thanks
How long would it take for CYGX to meet India's drug regulations?
I know in the U.S. it takes around a decade for a new drug process to be completed.
CYGX has talked about how in the U.S. they might be able to combine phases I and II, however isnt Phase III the longest?
How much time would CYGX cut off if they were able to combine the phases.
Is CYGX using its technology to treat HIV? If they have the potential to do so, then they should definitely pursue.
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-28-2004/0002161678&...
http://biz.yahoo.com/prnews/040323/latu043_1.html
Here is a link to the CytRx Corporation (Nasdaq: CYTR) article.
CytRx Corporation has made headlines today with a novel DNA HIV vaccine candidate. This technology appears to be in the same ball park as CYGX's. Is CYGX in trouble with this other company's results or is CYGX trying to yield a cure from its technology instead of a vaccine?
Thanks Neo 43 for answering my question the other day. Your explanation was very helpful!
I have tried to contact Markland various times through email and telephone and they never return my calls.
What gives?
When will CYGX announce the results of its preclinical herpes treatment in animals and when will they start testing in humans?
CytoGenix should be starting the human trials for their herpes drug soon. An announcement would bolster this stock up quite a bit.
CytoGenix must catch GSK. Asset-backed Glaxo-Smith Kline is a major heavyweight in the drug industry. It's number 2 behind PFE (as most of you know).
http://biz.yahoo.com/rc/031231/health_herpes_1.html
GSK also has a major stake in the herpes market, which appears to be growing after today's announcement.
Although GSK has not come up with a cure for herpes, and this Valtrex,which has been out for a while, has some unpleasant side-effects, GSK has a vaccine in the pipeline favoring women for thwarting herpes contraction.
GSK also has a ton of cash and is moving fast to obliterate herpes.
GSK's progress is commendible, but CYGX's gene silencing certainly sounds much more promising.
I just hope CYGX reaches a cure before GSK.
Where is this company located?
Is anyone interested in this slightly dated news?
Bidder Group Announces Tender Offer for B.V.R. Systems
Friday November 21, 6:00 am ET
TEL AVIV, Israel, Nov. 21 /PRNewswire-FirstCall/ -- A bidder group led by Aviv Tzidon together with Aeronautics Defense Systems Ltd. and iTS Technologies Pte Ltd. announced today that it has commenced a tender offer for B.V.R. Systems (1998) Ltd. (BVRSF.PK). In the offer, CHUN Holdings Ltd., an Israeli entity formed by the bidder group, is offering U.S.$0.18 in cash for each ordinary share of B.V.R. Systems. The transaction has a total net value of approximately $1.9 million.
The board of directors of B.V.R. Systems has discussed the advisability of our offer and has decided to recommend to the shareholders that they accept our offer. The bidder group has agreed, if the offer is completed successfully, to extend a $5 million line of credit to B.V.R. Systems.
The tender offer is conditioned upon a tender of a number of shares sufficient so that CHUN Holdings Ltd. will own or control at least 48% of the issued share capital of B.V.R. Systems. The offer is not conditioned on obtaining financing. The bidder group has deposited the full amount of cash payable in the tender offer in a trust account for the benefit of B.V.R. Systems.
The full terms and conditions of the offer are set forth in the tender offer materials to be filed with the appropriate regulatory agencies and mailed to B.V.R. Systems registered shareholders.
B.V.R. Systems (1998) Ltd. is a world leader in advanced defense training and simulation systems.
Shareholders are urged to read the tender offer statement and other relevant documents that will be filed with the U.S. Securities and Exchange Commission by CHUN Holdings Ltd. Such documents may be examined on the Securities and Exchange Commission Internet site (http://www.sec.gov). Shareholders also will be able to obtain a free copy of the relevant documents by contacting Orly Tsioni at Yigal Arnon & Co. 1 Azrieli Center Tel-Aviv 67201 Israel Telephone: 011-972-3-608-7842.
--------------------------------------------------------------------------------
Source: B.V.R. Systems (1998) Ltd.
This article is a bit dated but insightful.
REVA, Inc. Acquires Regional Wireless Networks and Expands Further into the Wireless Internet Market
Wednesday November 5, 1:36 pm ET
CULPEPER, Va.--(BUSINESS WIRE)--Nov. 5, 2003--REVA, Inc. (OTCBB:RVIA - News) announced today that it has signed a definitive agreement to acquire Regional Wireless Networks (RWN), a Texas-based Company specializing in wireless communications.
Pursuant to their agreement, RWN will become an independent business unit under REVA, Inc.'s corporate umbrella. RWN (www.rwnetworks.net) was acquired with the combination of REVA, Inc.'s restricted stock, cash and other considerations. This acquisition provides a stronger revenue and customer base for REVA as it enters the wireless communication market. Mr. Cameron Deal, former President of RWN, will remain as a consultant to REVA, Inc.
RWN is headquartered in Wichita Falls, and provides ultra high speed (1.5MBS) symmetrical data services to an approximate 240 square mile area with an estimated client base of 100,000. This wireless technology is used to provide Internet Services and enable broadband solutions to users across the country in non-metropolitan areas where broadband is limited or non-existent.
RWN currently provides wireless services in over 20 cities and plans to expand into other locations. Completion of this acquisition broadens the range of REVA Wireless services from Oklahoma to the Dallas/Fort Worth, Texas area. The additional substantial span of coverage by the acquisition expands REVA's business model in the wireless internet industry.
CURRENT BUSINESS INFORMATION
REVA, Inc. historically is a developer and manufacturer of Security & Surveillance, TeleHealth, and Video Compression systems. The Company designs and manufactures technology and products for the video communication market. The Company's remote video communication products can transmit (via compression) video, audio, and data over various communication media at speeds that far exceed those of its competitors.
"Chemical drugs are so last millennium" is what we will all be saying in 10 years.
CytoGenix is the future of medicine!
This recent drop in share price is just another buying opportunity.
If it drops lower than 30 cents, then you have to dump all your loot into CYGX.
Support of Outside Research: This section, which is under the "CEO's Update" of CytoGenix's website, lists 3 scientists from Columbia, Baylor, and Yale.
The section says, "The Company continues supporting three (3) Sponsored Research Agreements (SRA)" and lists them.
I took it upon myself to contact Dr. Peter Glazer at Yale University via email with some questions about his involvement with CYGX.
Dr. Glazer promptly responded with an email stating that he no longer has a research agreement with CYGX, however, they still use his name as an ongoing research partner.
He did not provide me with any insight about his involvement with CYGX either.
CYGX does not update their site as frequently as other biotechs and with the move going on I would expect any updates to be even more belated. However, this is old news and I contacted Dr. Glazer back in the early Fall.
It's not a huge deal that CYGX continues to use his name, but with all the recent preeminent additives I can't help but wonder if Glazer still being listed is a mistake or perhaps just a way to use his prestigious name to attract interest.
Honestly, by corporations was tough to come by in the late 90's boom. A little glitch like this is not a big deal, but a snowball has to start rolling somewhere.
If Glazer's listing is an honest mistake, then CYGX should take notice of this and list his agreement in the past tense.
I still support CYGX 100% and based on what they have been saying, I believe that they have the potential to someday change the world of medicine as we know it.
This just took me back a little bit.
If I still had the email I would post it, but I don't.
Dr.Glazer was very easy to get in touch with, and I encourage anyone to do the same.
I would also contact the other two listees, Dr. Stein and Dr. DeMayo. I don't now if their agreements are still ongoing.
There seems to be some apprehension about CytoGenix's cash position, and rightfully so. After reading the 10QSB I can see why.
This company has made agreements with India and China to market their products overseas, and this should bring in cash.
However, other massive, asset-backed companies, such as Glaxo-Smith Kline are developing products to combat the Herpes virus too, as well as HIV, cancer, and psorisis. Antigenetics (whose stock soared today) also has a strong pipeline of similar products.
I was impressed to hear on the MoneyTV interview that CYGX might be able to convince the FDA to allow them to combine Phase 1 and Phase 2. That would save a lot of time and money.
One suggestion though, let's not spread the word to everyone about this company. I like accumulating shares under a dollar of a company that has the potential to revolutionize modern drugs.
Wall Street has already taken notice of this company. In fact, CYGX has come a long way in a short amount of time. I don't know if anyone here was into this company when its' stock was trading at a mere 2 cents a share way back in May. If you were more power to you, because you must have already made a bundle.
If the company produces favorable results the word will get out.
Thanks